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Healthcare workers (HCWs) are an important priority group for vaccination against influenza, yet, flu vac-
cine uptake remains low among them. Psychosocial studies of HCWs’ decisions to get vaccinated have
commonly drawn on subjective expected utility models to assess predictors of vaccination, assuming
HCWs’ choices result from a rational information-weighing process. By contrast, we recast those deci-
sions as a commitment to vaccination and we aimed to understand why HCWs may want to (rather than
believe they need to) get vaccinated against the flu. This article outlines the development and validation
of a 9-itemmeasure of cognitive empowerment towards flu vaccination (MoVac-flu scale) and an 11-item
measure of cognitive empowerment towards vaccination advocacy. Both scales were administered to 784
frontline NHS HCWs with direct patient contact between June 2014 and July 2015. The scales exhibited
excellent reliability and a clear unidimensional factor structure. An examination of the nomological net-
work of the cognitive empowerment construct in relation to HCWs’ vaccination against the flu revealed
that this construct was distinct from traditional measures of risk perception and the strongest predictor
of HCWs’ decisions to vaccinate. Similarly, cognitive empowerment in relation to vaccination advocacy
was a strong predictor of HCWs’ engagement with vaccination advocacy. These findings suggest that
the cognitive empowerment construct has important implications for advancing our understanding of
HCWs’ decisions to vaccinate as well as their advocacy behavior.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction remains low among HCWs. In Europe, few countries actively mon-Infections from the Influenza virus, commonly known as ‘‘the
flu”, represent a hazard for healthcare facilities where sudden out-
breaks of illness can lead to high morbidity and mortality in vul-
nerable patients [1,2]. Because they work in close proximity to
these patients, healthcare workers (HCWs) are at risk of becoming
infected themselves and of infecting other patients. Annual vacci-
nation remains the most effective means to manage the spread
of the flu and prevent nosocomial influenza [3]. HCWs are there-
fore considered an important priority group for vaccination against
the flu by health organisations and government bodies [4–6]. In
England, the national 2016/2017 Flu plan aims to achieve flu vac-
cination for 75% of HCWs with direct patient contact and primary
care providers [7]. Despite this emphasis, flu vaccine uptakeitored HCWs’ uptake of the flu vaccination between 2010 and
2012. Those who did generally reported less than 50% uptake [8].
In England, only 50.8% of all HCWs with direct patient care were
vaccinated against the flu during the 2015/2016 flu season, with
wide variations in uptake between NHS Trusts from as low as
10.9% to as high as 83.5% [9].
Increasingly, focus has shifted towards a better understanding
of the psychosocial determinants of HCWs’ personal decision to
receive the flu vaccine or not [10]. A number of studies have thus
drawn on decision-making models to assess predictors of vaccina-
tion [11]. These models are derived from the concept of ‘subjective
expected utility’ [12], and assume that HCWs’ choices result from a
rational analysis of risks and benefits associated with all possible
choice alternatives. Among the most commonly used theories
within this overarching approach, we find the Health Belief Model
(HBM) [13] and the Theory of Planned Behavior (TPB, [14]).
According to these models, uptake is driven by HCWs’ belief that
their susceptibility to contamination by the flu is high, and the
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HCWs’ belief that vaccination comes with severe side effects (high
costs) coupled with the belief that it is not effective (low benefits).
Both the TPB and HBM models have been ‘‘augmented” over the
years with socio-cognitive variables (e.g., perceived attitudes of
significant others towards vaccination) and perceived control
(e.g., confidence in one’s ability to get vaccinated).
A limitation of such models is that they conceive decision-
making as deliberate and rational information processing. They
highlight why HCWs may feel they need to be vaccinated given
their beliefs associated with vaccination, with a balance of benefits
and costs. As such, they implicitly assume that HCWs who decline
the flu vaccination do so because they hold ‘‘inaccurate” beliefs
about the flu and its vaccine. This in turn, calls for interventions
aimed at ‘‘debiasing” HCWs through educational interventions
seeking to reestablish scientific facts. Yet, education aiming to
reassure can be surprisingly unhelpful for those who are already
doubting or challenging vaccination, leading instead to greater
negativity towards vaccination [15,16].
In the present study, we propose and test a complementary the-
oretical framework, namely the cognitive model of empowerment
(CME) [17] to study HCW flu vaccination behaviors. The CME con-
ceives empowerment as an intrinsic motivation to engage in a pur-
poseful behavior. These positive experiences are assumed to arise
from four distinct cognitive assessments of the behavior:
(1) the feeling of value, or how much one cares about the pur-
pose of the behavior;
(2) the feeling of impact, or the belief that the behavior makes a
difference in achieving its purpose;
(3) the feeling of knowledge, or the belief that one has the skills
and knowledge to perform the behavior when he or she
tries; and
(4) the feeling of autonomy, or the belief that the initiation of the
purposeful behavior is self-determined.
We recast the decision to get vaccinated as a commitment to vac-
cination (rather than a rational information-weighing process) as we
aim to understand why HCWs may want to get vaccinated. To our
knowledge, this is the first attempt to apply and empirically evaluate
the CME in the context ofHCWsfluvaccination. Our primary aimwas
to develop a reliable measure of levels of empowerment towards flu
vaccination for HCWs. A secondary aimwas to examinewhether this
framework could also be extended to vaccination advocacy. Finally, a
third, conceptual aimwas to test whether the CME could be success-
fully applied to both vaccination decisions and vaccination advocacy.
2. Methods
2.1. Overview
The project involved the development of an online question-
naire to gather information on HCWs views on the flu vaccination.
The questionnaire measured their intrinsic motivation to get vacci-
nated against the flu through four components: the extent to
which they felt vaccination was (a) important, (b) impactful, and
the extent to which they felt (c) knowledgeable about vaccination
and (d) autonomous in their decision to get vaccinated.
2.2. Measures
2.2.1. Motors of influenza vaccination acceptance (MoVac-flu) and
motors of engagement with vaccination advocacy (MovAd)
We measured each of the four dimensions of cognitive empow-
erment based on the CME (value, impact, knowledge, and auton-
omy) with three survey items, resulting in a 12-item scale for fluvaccination (MoVac-flu) and a 12-item scale for vaccination advo-
cacy (MovAd) (see Supplemental materials). Items were initially
generated by the first author and reviewed by the research team
as well as two subject matter experts (one medical doctor and
one industry specialist) for clarity and sound language structure.
The content validity of the items was initially confirmed by a pilot
study with a small sample of HCWs [18].
2.2.2. Other predictors of vaccination behavior
Participants’ perceptions of the threat posed by the flu virus
were measured using three items: the perceived severity of the
flu, the susceptibility to be negatively affected by the flu, and the
subjective likelihood of contracting the flu without the flu vaccine.
Subjective perceptions of the threat posed by the flu vaccine were
measured using three items: the perceived (lack of) safety of the flu
vaccine, the fear of vaccination, and concerns for side-effects (see
Supplemental materials for item wordings).
2.2.3. Behavioral measures
Participants were asked whether they had been vaccinated
against the flu in the 2013/2014 flu season, the extent to which
they agreed they had encouraged their patients to get vaccinated
against the flu, measured on a 7-point Likert scale ranging from
1 (Strongly disagree) to 7 (Strongly agree), and whether they knew
if their line manager within the hospital was vaccinated against the
flu.
2.3. Procedure
Data collection took place between 19th June 2014 and 11th
July 2014 at a single metropolitan hospital group. The study was
introduced as aiming to find out healthcare professionals’ thoughts
about vaccination, emphasizing there were no right or wrong
answers to the survey. Participation was voluntary and partici-
pants were free to withdraw at any time, without giving any rea-
son. Duration to complete the questionnaire was estimated to be
about 5–7 min. Participants were invited to take part in the study
through emails, hospital newsletters, and posters. The question-
naire included a brief introduction and 40 survey questions. Partic-
ipants could answer questions in their own time. Upon answering
all questions, they were offered a voucher for a free coffee from a
nearby coffee shop or 1 in 200 chances to win an £80 gift voucher.
The study protocol was submitted to a research ethics committee
and approved prior to the data collection.
2.4. Statistical analyses
Statistical analyses were undertaken using SPSS for Mac Version
23 Release 23.0.0.2. Parallel analyses were used to determine the
number of components to retain in an Exploratory Factor Analysis
for both the MoVac and MovAd scales. Principal Component Anal-
ysis with oblimin rotation was used to examine item loadings and
reliability analyses based on Cohen’s alpha were used to explore
the dimensionality and internal consistency of the scales.
The incremental validity of the MoVac-flu scale was assessed
using hierarchical binary logistic regression analysis to determine
odds ratios and 95 per cent confidence intervals with 2013–14
influenza vaccination status (1 = vaccinated, 0 = not vaccinated)
as a discrete outcome measure. Demographics were entered in
the first step, risk perception measures of the flu and the flu vac-
cine were entered in the second step, and knowledge of line man-
ager’s vaccination against the flu in the third step of the analysis as
per standard practice. Finally, the MoVac-flu score, computed as
the average across the individual MoVac-flu items, was entered
in the fourth and final step. To allow comparison of coefficient
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from 0 to 1 [19].
The incremental validity of the MovAd scale was assessed using
a hierarchical regression analysis with advocacy behavior as a con-
tinuous outcome to determine regression coefficients and confi-
dence intervals. We only included demographics in the first step
as we had no specific hypothesis about other predictors of vaccina-
tion advocacy. We entered the MovAd scores, computed as the
average of the MovAd item scores, in the second and final step.
3. Results
3.1. Participants
A total of 1015 frontline NHS HCWs with direct patient contact
completed the online questionnaire. Responses were screened for
careless responding (see Supplemental materials for details). Alto-
gether, 23% of questionnaires were discarded and the final sample
included data from 784 individual respondents with no missing
data (representing about 10% of the HCWs with direct patient care
in this NHS Trust). Table 1 summarizes the demographic data.Table 1
Demographic characteristics of the sample.
Variable Job
Doctor Nurse or midwife Allied hea
N 88 283 233
Age
M 35.2 40.0 34.8
SD 11.2 10.1 9.4
18–29 years (%) 38.6 21.2 45.5
30–49 years (%) 52.3 65.4 46.8
50–65 years (%) 6.8 12.7 7.3
Over 65 years (%) 2.3 0.7 0.4
Gender
Female (n) 41 242 178
Male (n) 47 41 55
Table 2
List of final items, means, standard deviations, and factor loadings sorted by standardized
Dimension Item
MoVac-flu scale
1. Value It is important that I get the flu jab. (VacVal1)
The contribution of the flu jab to my health and well-being is very i
The flu jab plays an important role in protecting my life and that of
2. Impact Vaccination is a very effective way to protect me against the flu. (Va
Vaccination greatly reduces my risk of catching the flu. (VacImp2)
Getting the flu jab has a positive influence on my health. (VacImp3)
3. Knowledge I know very well how vaccination protects me from the flu. (VacKno
I understand how the flu jab helps my body fight the flu virus. (Vac
4. Autonomy I can choose whether to get a flu jab or not. (VacAut1)
MovAd scale
1. Value Vaccination is an important topic I want to discuss with others. (Ad
It is important that I mention the topic of vaccination to others. (Ad
It matters that I talk openly about vaccination with other people. (A
2. Impact When I talk openly about vaccination, it has a positive impact on pe
If I discuss vaccination, it will very much change others’ views on th
People’s opinions of vaccination can really be influenced by the con
3. Knowledge I am confident I can answer questions that others could ask me abo
I know exactly how to talk about vaccination with others. (AdvKno2
I feel able to discuss vaccination. (AdvKno3)
4. Autonomy I decide whether to have conversations on vaccination with others.
Discussing vaccination with others is entirely my choice. (AdvAut3)
Note. The range of individual item scores was [1,7] on all items for both MoVac-flu and3.2. Exploratory factor analysis (EFA) and reliability analysis
3.2.1. MoVac-flu
Preliminary analyses revealed that the second and third items
from the Autonomy subscale as well as the second item from the
Knowledge subscale were outliers and were therefore eliminated
(see Supplemental Materials for details). A parallel analysis with
all 9 remaining items suggested one component. The exploratory
factor analysis revealed this component had an eigenvalue of
6.40 and accounted for 71% of the variance. The upper half of
Table 2 lists the items and factor loadings for the MoVac-flu items.
The MoVac-flu scale exhibited excellent internal consistency with
a Cronbach’s a of 0.946.
3.2.2. MovAd
Preliminary analyses revealed that the second item from the
Autonomy subscale was an outlier and was therefore eliminated
(see Supplemental Materials for further details). A parallel analysis
with the 11 remaining items suggested one component. The
exploratory factor analysis revealed this component had an eigen-
value of 6.74 and accounted for 61% of the variance. The lower halfTotal
lth professional Healthcare assistant Student
132 48 784
35.8 24.9 36.26
11.2 5.1 10.63
40.2 89.6 37.8
47.0 10.4 51.9
12.9 – 9.7
– – 0.6
83 34 578
49 14 206
loadings for the MoVac-flu and the MovAd scales.
M SD Standardized loadings
5.08 1.63 0.91
mportant. (VacVal2) 4.90 1.67 0.86
others. (VacVal3) 4.98 1.73 0.93
cImp1) 4.95 1.71 0.90
4.92 1.66 0.87
4.71 1.63 0.81
1) 5.10 1.55 0.87
Kno3) 5.22 1.52 0.87
5.46 1.64 0.49
vVal1) 4.99 1.6 0.84
vVal2) 4.96 1.51 0.85
dvVal3) 5.05 1.47 0.85
ople’s beliefs. (AdvImp1) 4.85 1.66 0.77
is topic. (AdvImp2) 4.79 1.41 0.79
versations I have with them. (AdvImp3) 4.87 1.47 0.84
ut vaccination (AdvKno1) 4.76 1.47 0.79
) 4.66 1.52 0.75
5.02 1.44 0.79
(AdvAut1) 4.93 1.51 0.70
5.17 1.49 0.62
MovAd scales.
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Finally, a reliability analysis revealed the MovAd scale exhibited
excellent internal consistency with a Cronbach’s a of 0.935.3.3. Incremental validity of the MoVac-flu scale
Next, we examined whether the MoVac-flu scale accounted for
vaccination behavior over and above demographic statistics, risk
perception beliefs, and social cues. Table S1 in the Supplemental
materials presents the mean values, standard deviations and
observed frequencies for the predictor variables as a function of
HCWs’ flu vaccination behavior. Table 3 provides a summary of
the analysis. Taken together, demographics variables did not pro-
vide insight into flu vaccination behavior, LR v2(3) = 6.17,
p = 0.104. The risk perception variables significantly predicted vac-
cination behavior over and above the demographic variables, LR
v2(6) = 88.2, p < 0.001. The strongest predictor was the perceived
risk of getting the flu without the vaccine: a 1-point increase on
the 7-point Likert scale used to measure perceived risks resulted
in an increase of HCWs’ odds of being vaccinated by a factor of
4.56, 95% CI [2.68, 7.75], Wald v2(1) = 31.4, p < 0.001. Conversely,
the biggest detractor was concern about safety of the vaccine, a
1-point increase on the 7-point Likert scale resulted in a decrease
of the odds of vaccination by a factor of 3.58, 95% CI [1.70, 7.58],
Wald v2(1) = 11.2, p < 0.001. At Step 3, knowledge of the line man-
ager’s vaccination further improved predictability, Step LR v2(1)
= 38.3, p < 0.001. It was the second most influential predictor after
the perception of the likelihood of contracting the flu without the
flu vaccine, OR = 4.76, 95% CI [2.87, 7.91], Wald v2(1) = 36.2,
p < 0.001. More importantly for our present purpose, adding the
MoVac-flu score in Step 4 made a further significant contribution
to predictability, Step LR v2(1) = 32.6, p < 0.001. In fact, the
MoVac-flu score was the strongest predictor of all: a 1-point
increase on the cognitive empowerment measure resulted in
increased odds of vaccination by a factor of 9.74, 95% CI [4.35,
21.78]. The overall model contributed to predict vaccination
behavior above and beyond the baseline model including onlyTable 3
Summary of the binary logistic regression analysis predicting flu vaccination behavior.
Predictors b
Step 1
Step 1: Demographic variables
Gendera 0.13
Age 1.28*
Qualification levelb 0.10
Step 2: Risk perception variables
Flu likelihood
Flu susceptibility
Flu severity
Vaccine (lack of) safety
Vaccine side effects
Vaccine fear
Step 3: Social variable
Line manager vaccinationc
Step 4: Cognitive empowerment
MoVac-flu score
Note. All variables were rescaled on a [0, 1] scale to allow comparing weights across predic
Percent correct = 57.6%. For Step 2, R2 = 0.154 (Nagelkerke), Step LR v2(6) = 88.2, p < 0.0
v2(1) = 38.3, p < 0.001, 2LL = 922.8, Percent correct = 65.8%. For Step 4, R2 = 0.258 (Nag
a 1 = Female, 0 = Male.
b 1 = Doctor, 0.75 = Nurse or Midwife, 0.50 = Allied health professionals, 0.25 = Health
c 1 = Yes, 0.5 = Don’t know, 0 = No.
* p < 0.05.
** p < 0.01.
*** p < 0.001.the intercept, Model LR v2(11) = 165.3, p < 0.001 and provided a
good fit to the observed data, Hosmer and Lemeshow’s v2(8)
= 10.3, p = 0.24.3.4. Incremental validity of the MovAd scale
A secondary objective was to examine whether the MovAd scale
contributed to explain advocacy behavior above and beyond demo-
graphics. Fig. S5 in the Supplemental materials presents the scat-
terplot of advocacy behavior and MovAd scores. Table 4 provides
a summary of the analysis. Age was a significant predictor of advo-
cacy behavior at Step 1 and was positively related to advocacy:
older HCWs were more likely to advocate vaccination, B = 0.02,
95% CI [0.01, 0.03], t(771) = 3.11, p = 0.002. This variable was no
longer a significant predictor (p = 0.07) when controlling for the
MoVad scores at Step 2. The MoVad score, however, was a signifi-
cant and strong predictor of vaccination advocacy behavior,
B = 0.75, 95% CI [0.67, 0.82], t(770) = 19.07, p < 0.001.4. Discussion
4.1. Main findings
In this study, we sought to apply the Cognitive Model of
Empowerment model (CME) [17] to flu vaccination behavior. To
empirically evaluate the potential of this model, we developed a
new short scale, the 9-item MoVac-flu scale, which measures cog-
nitive empowerment towards vaccination against the flu. We also
extended this framework to account for vaccination advocacy
behaviors in this professional group. To this end, the 11-item
MovAd scale was developed to measure cognitive empowerment
towards vaccination advocacy. Results indicated that both scales
had excellent internal validity and contributed to predicting
behavior above and beyond standard psychosocial variables. The
MoVac-flu scores made a distinct contribution to the understand-
ing flu vaccination behavior among HCWs while the MovAd scale
was a better predictor of advocacy behavior than age and genderStep 2 Step 3 Step 4
0.23 0.20 0.11
0.49 0.47 0.40
0.18 0.07 0.10
1.52*** 1.60*** 1.41***
1.02** 1.08** 0.72
0.78** 0.63* 0.15
1.28*** 1.16** 0.89*
1.04** 1.08** 1.02**
0.31 0.38 0.59
1.56*** 1.51***
2.28***
tors. For Step 1, R2 = 0.01 (Nagelkerke), Step LR v2(3) = 6.17, p = 0.10, 2LL = 1049.4.
01, 2LL = 961.1, Percent correct = 65%. For Step 3, R2 = 0.212 (Nagelkerke), Step LR
elkerke), Step LR v2(1) = 32.61, p < 0.001, 2LL = 890.2, Percent correct = 70.3%.
care assistant, 0 = Student.
Table 4
Summary of the linear regression analysis predicting flu vaccination advocacy
behavior.
Predictors b
Step 1 Step 2
Step 1: Demographic variables
Gendera 0.03 0.02
Age 0.11** 0.05
Step 2: Cognitive empowerment
MovAd score 0.57***
Multiple R 0.11 0.57
Delta R2 0.01** 0.32***
Adjusted R2 0.01 0.33
Note. For Step 1, Model F(3,770) = 5.15, p = 0.002. For Step 2, Step F(1,769) = 356.86,
p < 0.001, Model F(4,769) = 94.86, p < 0.001.
a 1 = Female, 0 = Male.
* p < 0.05.
*** p < 0.001.
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CME could be successfully applied to better account for both vac-
cination decisions and vaccination advocacy behaviors.4.2. Strengths and limitations
This is, to our knowledge, the first attempt to model HCWs’ flu
vaccination uptake based on a framework of motivational factors,
namely the Cognitive Model of Empowerment model (CME). Test-
ing the applicability and elements of the validity of the CME
allowed us to reframe the decision to get vaccinated against the
flu as a motivated commitment, rather than a choice driven by a
rational evaluation of costs/benefits. This preliminary study, how-
ever, is not without limitations. First, since our purpose was
exploratory, we chose to rely on a self-selected sample: participa-
tion was voluntary and participants were compensated for their
time. Although this resulted in a large sample, we cannot be certain
that the views expressed are representative of the general popula-
tion of HCWs. Future research may use probability sampling to
address this shortcoming. Second, since HCWs are difficult to
access, we chose to use a limited number of pretested items to
assess each component of the CME so that the survey completion
would be swift. While this may have increased participation rate,
it may also have limited our ability to validate the four-
dimensional factor structure suggested by the CME in the current
sample. Still, future research may address this shortcoming by
using a larger set of items to measure each of the four components
of the CME construct (perceived value, impact, knowledge, and
autonomy). Third, the Cronbach’s alphas for the MoVac and MovAd
scales were above the recommended maximum alpha value of 0.90
[20] (but see also [21]), possibly suggesting that cognitive empow-
ermentmay bemeasuredwith a smaller number of items without a
significant loss of internal consistency. However, since Cronbach’s
alpha is a property of the scores on a test in a particular sample of
participants, future research will need to establish that the high
value observed is a property of the scale rather than a characteristic
of the particular sample used in this study [20]. Fourth, as we could
not access objective measures of flu vaccination and advocacy
behavior, our analyses of the incremental validity relied on self-
reported measures of vaccination and advocacy behaviors.
Although possibly biased, self-report measures are generally
viewed as an acceptable proxy for actual past behavior (as opposed
to future behavioral intentions) [22]. Finally, the study was intro-
duced as aiming to finding out HCWs’ thoughts about vaccination.
While being open about the purpose of the survey is good practice
to ensure informed consent, this could have resulted in selectionbias. A total of 56.7% participants reported receiving the flu shot
in our sample, approximately 10% more than the official record of
doses distributed in the site population during this season.
5. Implications for policy and practice
Our findings highlight the promise of including considerations
of cognitive empowerment above and beyond perceptions of risk
and benefits in better understanding vaccine hesitancy issues.
The MoVac-flu and MovAd short scales developed can also form
a useful toolkit to address vaccine hesitancy among HCWs. For
example, Kassianos, et al. [23] used these scales to explore and pro-
file HCWs’ level of engagement towards flu vaccination and vacci-
nation advocacy across six European countries. Their results
showed that hesitancy was mostly driven by neutral (rather than
negative) empowerment towards flu vaccination and advocacy.
Thus, the MoVac-flu and MovAd short scales can be used as tools
to spot the presence and prevalence of HCWs with lower levels
of motivation to vaccinate. Such an increase in the granularity of
our understanding the motors of vaccination could pave the way
for designing more bespoke, and therefore potentially more effec-
tive, interventions to target vaccine hesitancy. For example, the
identification of the main driver(s) of hesitancy among the four
CME assessments of vaccination behavior (value, impact, knowl-
edge, or autonomy) could provide useful insights for hospital
administrators in charge of designing communication campaigns
or staff development strategies.
6. Conclusions
We found that the CME, operationalised through the MoVac-flu
andMovAd scales, offers a promising way to capture HCWs’ motiva-
tions to get vaccinated against the flu and their ability to advocate
towards this behavior and in a useful and psychometrically robust
manner. Our data offer some reassurance that these short scales
can be used effectively with this sample. We propose that further
research be conducted within this large and important professional
group – sowe can better understand the determinants of thesemoti-
vations and also what interventions may positively impact on them.
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